Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

著者: Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, Alexa P. Kollmeier, Elizabeth C. Hsia, Ramanand A. Subramanian, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T Ritchlin - The Lancet 2020 被引用: 322